 |
 |
The following information is NOT intended to endorse drugs or recommend therapy. While these reviews might be helpful, they are not a substitute for the expertise, skill, knowledge and judgement of healthcare practitioners in patient care.
Learn more about Inlyta.
Condition  |
Reviews | Compare | Avg. Ratings |
|
|---|---|---|---|---|
| Renal Cell Carcinoma | 0 reviews | 19 medications | ||
No reviews have yet been submitted. Be the first to review this drug.
ASONEP Trial to Study Effects of Lpath's Anti-S1P Antibody in Subjects With Renal Cell Carcinoma SAN DIEGO, May 23, 2013 (GLOBE NEWSWIRE) -- Lpath, Inc....
An experimental drug that taps the power of the body's immune system to fight cancer is shrinking tumors in patients for whom other treatments have failed, an...
Cholesterol-lowering statin drugs that are taken by millions of Americans might also improve survival from a type of kidney cancer called renal cell carcinoma,...
Looking for answers? Ask a question or go join the Inlyta support group to connect with others who have similar interests.
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
Data sources include Micromedex™ (updated May 16th, 2013), Cerner Multum™ (updated May 20th, 2013), Wolters Kluwer™ (updated Apr 30th, 2013) and others. To view content sources and attributions, refer to our editorial policy.
Copyright © 2000-2013 Drugs.com. All rights reserved.
We comply with the HONcode standard for trustworthy health information.
Verify here
